Gossamer Bio Inc Dossier - Source-backed chat

Gossamer Bio Inc

GOSSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.68

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.93Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $66.9M

Enterprise Value $25.7M

Shares Outstanding 6.1M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Gossamer Bio is at a critical regulatory and financial crossroads. The company's lead asset, seralutinib, narrowly missed its prespecified statistical threshold (alpha of 0.025) in the Phase 3 PROSERA trial for pulmonary arterial hypertension (PAH), despite showing a positive placebo-adjusted 6MWD improvement of 13.3 meters (p=0.032). While the company is actively engaging with the FDA and targeting an NDA submission in September 2026, it faces severe going-concern risks with a cash runway extending only into Q1 2027. A massive debt restructuring to exchange 64% of its $200M convertible notes due 2027 for new notes due 2030 will significantly dilute existing equity holders, making a Hold recommendation appropriate until regulatory clarity and long-term financing are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$0.28

Mean target$3.86

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA refuses to file the NDA or requires an additional Phase 3 trial due to the PROSERA primary endpoint miss. The debt exchange fails to fully resolve liquidity pressures, or the resulting massive dilution wipes out current equity value, forcing a severe restructuring or liquidation as cash runs out in early 2027.

Base CaseCentral scenario

The FDA accepts the NDA filing for seralutinib in PAH based on the totality of the PROSERA data (including positive secondary endpoints and subgroup analyses) despite the primary endpoint missing the strict alpha threshold. The convertible debt exchange is fully completed, extending the debt maturity to 2030, and the company secures additional dilutive equity or partnership funding to extend its cash runway past Q1 2027.

Bull CaseUpside scenario

The bullish thesis for Gossamer Bio centers on the clinical and commercial potential of its lead drug candidate, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Following a productive Pre-NDA Type B meeting with the FDA, the company is on track to submit its New Drug Application (NDA) for seralutinib in PAH in September 2026, potentially leading to FDA approval by Q3 2027. Additionally, the reacquisition of global development and commercialization rights from Chiesi Group secures the substantial majority of the program's long-term economics for Gossamer's shareholders.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Seralutinib demonstrated a positive clinical signal with a 13.3m placebo-adjusted 6MWD improvement (p=0.032) and strong supportive secondary/subgroup data.
Global partnership with Chiesi provides robust development cost-sharing and validation of the inhaled seralutinib platform.
Proactive capital structure management via the convertible note exchange offer reduces near-term debt maturity pressure by 64%.

Key Investment Risks

Substantial doubt exists regarding the company's ability to continue as a going concern, with current cash only funding operations into Q1 2027.
The Phase 3 PROSERA trial missed its prespecified statistical alpha, creating high regulatory risk for the planned September 2026 NDA submission.
The debt exchange and authorized share increase (from 700M to 4B shares) will result in massive equity dilution for existing stockholders.

Thesis Invalidation Triggers

FDA issues a Refusal to File (RTF) letter or explicitly requires another Phase 3 trial for seralutinib in PAH.
The company fails to secure additional capital or strategic partnerships by late 2026, accelerating going-concern insolvency.
The convertible debt exchange offer is terminated or fails to achieve the required high participation threshold.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.